AnaSpec Introduces Newest GO™ Peptides- Exendins

AnaSpec has added a wide selection of Exendin peptides to it’s GO™ Peptides line of on-demand peptides. Along with a host of popular Exendin peptides, AnaSpec’s GO™ Peptides line includes Fluorescein-Trp25-Exendin-4 (FLEX) and [Cys(HiLyteFluor 647 C2 maleimide)]-Exendin-4 - two exendin peptides that are not immediately available anywhere else.

Fluorescein-Trp25-Exendin-4 (FLEX) is Exendin-4 with a fluorescein covalently attached to Trp at position 25. Useful for binding and characterization studies of the human GLP-1 receptor, FLEX is equipotent to GLP-1 (7-36)-amide and Exendin-4 as an inhibitor of [125I]-GLP-1 binding to the human GLP-1 receptor stably expressed in CHO cells.[1] [Cys(HiLyte Fluor™ 647 C2 maleimide)]-Exendin -4 is Exendin-4 with an additional Cys added to the N-terminus. AnaSpec’s patented HiLyte Fluor 647 (Ex/Em=650 nm/675 nm) is attached to the Cys thiol moiety.

Exendin-3 and Exendin-4 are 39-amino acid peptides from exocrine glands that share about 50% sequence identity to Glucagon-Like-Peptide-1 (GLP-1) and are potent GLP-1R agonists. 2,3 Exendin-3 stimulates increases in cellular cAMP and amylase release from dispersed guinea pig pancreatic acini.[4] Exendin-4 was originally isolated from the saliva of the lizard Heloderma suspectum. It is an insulinotropic agent which improves glucose tolerance in humans and animals with diabetes. It increases insulin sensitivity via a PI-3-kinase-dependent mechanism. In the human fetal pancreas, the proliferation and differentiation of endocrine precursor cells into insulin-producing ß-cells can be positively regulated by Exendin-4.[5] Exendin-4 is an agonist and Exendin (9-39) is an antagonist of the action of GLP-I (7-36) amide on arterial blood pressure and heart rate [6].

References:
1. Chicchi GG. et al. Peptides 18, 319 (1997).
2. Goke, R. et al. J. Biol. Chem. 268, 19650 (1993).
3. Thorens, B. et al. Diabetes 42, 1678 (1993).
4. Eng, J. J. Biol. Chem. 265, 20259 (1990).
5. Movassat, J. et al. J. Clin. Endo. Metab. 87, 4775 (2002).
6. Barragan, JM. Regul. Peptides 67, 63 (1994).